EnChannel Medical, an innovator in cardiac electrophysiology, announced the completion of an oversubscribed Series B financing, raising $82.2 million (600 million RMB). The funding round was co-led by Dragonball Capital and existing investor Lilly Asia Ventures (LAV), with Lapam Capital’s continued support.
This financing marks one of the largest private investments in China’s medical device sector since 2023. And EnChannel’s previously completed its Series A round of $27.8 million (195M RMB) in August 2023.
Based in Guangzhou, with an R&D subsidiary in Irvine, California, EnChannel is positioned to expand its global innovation and advance its mission to transform AF care through data-driven, patient-specific therapy solutions.
What the funding will be used for: The proceeds from the Series B round will accelerate product development and advance clinical registration trials in China and internationally.
KEY QUOTE:
“EnChannel’s platform integrates full-chamber action-potential mapping with pulsed-field ablation to address long-standing unmet needs in atrial fibrillation treatment. We’re grateful for the strong support from new and returning investors and encouraged by early clinical data from our ongoing studies. Key results were presented at the Heart Rhythm Society Meeting in San Diego, held April 24-27.”
Jun Feng, CEO of EnChannel Medical
